ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

September 18, 2020

On September 24, a multinational consortium of organizations in the cancer field will host the annual World Cancer Research Day, which aims to raise awareness about the importance of further developing and boosting cancer research as a crucial part of slowing the diseases’ progression and improving survival rates and quality of life for those affected. This is particularly important as the total number of cancer cases rising.

September 16, 2020

The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Carolyn Hendricks, MD, FASCO, for her exceptional contributions and commitment to the Association’s advocacy efforts.

September 15, 2020

On September 13, President Trump signed an executive order (EO) aiming to address high prescription drug prices by tying payments for certain Medicare drugs to the costs the treatments sell for outside the United States (U.S.). According to the EO, prices for provider-administered drugs would be linked to a "most-favored-nation price" drawn from the lowest price among countries that have a similar per-capita gross domestic product.

September 9, 2020

The Association for Clinical Oncology (ASCO) today presented Representative Rosa DeLauro (CT-3) with the annual Congressional Champion for Cancer Care Award in recognition of her exceptional commitment to bipartisan support for cancer research and treatment. The award honors a Member of Congress who is a leading champion for patients and survivors of cancer, their families, and their cancer care teams.  

September 9, 2020

On September 4, 2020, the Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETOTM, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.​

September 4, 2020

The Association for Clinical Oncology (ASCO) today released a statement regarding concerns that the U.S. Department of Health and Human Services (HHS) rescission of all guidance and informal issuances related to the Food and Drug Administration’s (FDA) current oversight of the premarket review and approval process for laboratory developed tests (LDTs) puts the safety of cancer treatments at risk.

September 4, 2020

On September 2, the Centers for Medicare & Medicaid Services (CMS) released updates to the Inpatient Prospective Payment System (IPPS) final rule for fiscal year 2021, including updates to Medicare payment policies and payment rates for most acute care hospitals. Notably, CMS finalized its proposal to establish a Medicare Severity Diagnosis Related Group (MS-DRG) for  chimeric antigen receptor T-cell (CAR-T) services. 

September 4, 2020

ASCO has been notified about a recent safety update relating to the drug COPIKTRATM (duvelisib) under the Food and Drug Administration’s (FDA) Risk Evaluation and Mitigation Strategy (REMS) program.

September 2, 2020

While cancer remains the second leading cause of death in high-income countries, cancer-related mortality has been steadily declining thanks to a wide range of advances. Today, ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, and co-authors Sharyl Nass, PhD, Michelle M. Le Beau, PhD, and Edward J. Benz, Jr., MD, highlight the major advances in cancer care over the last 50 years as part of a special series of articles in the New England Journal of Medicine commemorating the 50 year anniversary of the National Academy of Medicine.

September 1, 2020

On Monday, August 23, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, and Stand Up To Cancer (SU2C) Health Equity Committee Chair Edith Perez, MD, met virtually to discuss the importance of health equity and the work ASCO and Stand Up To Cancer are doing to increase diversity in cancer research and treatment.

September 1, 2020

On September 1, 2020, the Food and Drug Administration approved azacitidine tablets (ONUREG®, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

September 1, 2020

On September 17, the American Society of Clinical Oncology (ASCO) will host ASCO Practice Leadership: E&M Codes For 2021. During this free webinar, Allison Hirschorn, Senior Coding and Reimbursement Specialist, Clinical Affairs at ASCO, will review new information and changes regarding the office and outpatient Evaluation and Management (E&M) services Current Procedural Terminology (CPT ®) codes (99202-99215), which go into effect January 1, 2021.

August 31, 2020

On September 16, the Association for Clinical Oncology (ASCO) will be hosting its first ever completely virtual Advocacy Summit. Oncology care providers from across the United States will meet with Members of Congress and their staff by phone or video to advocate for policies that will improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research.

August 27, 2020

The American Society of Clinical Oncology (ASCO) released its 2020 Workforce Information Systems (WIS) report, which assembles the latest available data on oncologist supply and demand in the United States to provide a close look at a critical segment of the workforce who care for people with cancer.

August 26, 2020

On August 25, 2020, the Centers for Medicare & Medicaid Services (CMS) released its third COVID-19-related interim final rule with comment period (IFC). Provisions from the rule impact hospital and laboratory COVID-19 reporting, as well as testing for Medicare beneficiaries. Comments are due 60 days after publication in the Federal Register.